» Articles » PMID: 12427501

Milk Thistle for the Treatment of Liver Disease: a Systematic Review and Meta-analysis

Overview
Journal Am J Med
Specialty General Medicine
Date 2002 Nov 13
PMID 12427501
Citations 51
Authors
Affiliations
Soon will be listed here.
Abstract

Purpose: Milk thistle, an herbal compound, is the dietary supplement taken most frequently by patients with chronic liver disease. We performed a systematic review of the literature to determine the efficacy and safety of this herb for the treatment of liver disease.

Methods: We searched English and non-English reports through July 1999 using thirteen databases and reference lists, and contacting manufacturers and technical experts. Reviewers independently screened all reports to identify randomized placebo-controlled trials that evaluated milk thistle for the treatment of liver disease. Outcomes of primary interest included mortality, histological findings on liver biopsy specimens, serum aminotransferase and albumin levels, and prothrombin times.

Results: Fourteen trials met inclusion criteria. Four trials reported outcomes for mortality among 433 participants. The overall summary odds ratio for mortality in the milk thistle group compared with placebo was 0.8 (95% confidence interval [CI]: 0.5 to 1.5; P = 0.6). Three trials assessed histology on liver biopsy; study quality was inversely associated with the likelihood of histological benefit for milk thistle compared with placebo. There were no differences in serum alanine aminotransferase, aspartate aminotransferase, or albumin levels, or prothrombin times, among participants assigned to milk thistle compared with those assigned to placebo. The only statistically significant difference was a greater reduction in alanine aminotransferase levels among patients with chronic liver disease assigned to milk thistle (-9 IU/L, 95% CI: -18 to -1 IU/L; P = 0.05), but this reduction was of negligible clinical importance and no longer statistically significant after limiting analyses to studies of longer duration or of higher quality. The frequency of adverse effects was low and, in clinical trials, indistinguishable from placebo.

Conclusion: Treatment with milk thistle appears to be safe and well tolerated. We found no reduction in mortality, in improvements in histology at liver biopsy, or in biochemical markers of liver function among patients with chronic liver disease. Data are too limited to exclude a substantial benefit or harm of milk thistle on mortality, and also to support recommending this herbal compound for the treatment of liver disease.

Citing Articles

Use of complementary and alternative medicine in patients with chronic liver diseases in Germany- a multicentric observational study.

Gittinger F, Rahnfeld A, Lacruz E, Zipprich A, Lammert F, Ripoll C BMC Complement Med Ther. 2024; 24(1):340.

PMID: 39313803 PMC: 11421120. DOI: 10.1186/s12906-024-04607-x.


The comparison of the effects of nano-silymarin and silymarin on high-fat diet-induced fatty liver of adult male rats.

Mohebbati R, Momeni-Moghaddam M, Asghari R, Abbasnezhad A, Ebrahim Zadeh Bideskan A, Salarbashi D Avicenna J Phytomed. 2024; 14(3):365-375.

PMID: 39086861 PMC: 11287026. DOI: 10.22038/AJP.2024.23734.


Complementary and alternative medicines and liver disease.

Philips C, Theruvath A, Ravindran R, Augustine P Hepatol Commun. 2024; 8(4).

PMID: 38563584 PMC: 10990366. DOI: 10.1097/HC9.0000000000000417.


Silymarin Synergizes with Antiviral Therapy in Hepatitis B Virus-Related Liver Cirrhosis: A Propensity Score Matching Multi-Institutional Study.

Huang C, Wu V, Wang C, Wu C, Huang Y, Chang S Int J Mol Sci. 2024; 25(6).

PMID: 38542062 PMC: 10970014. DOI: 10.3390/ijms25063088.


Silymarin enhances the response to oxytetracycline treatment in Oreochromis niloticus experimentally infected with Aeromonas hydrophila.

Sherif A, Toulan A, El-Kalamwi N, Farag E, Mahmoud A Sci Rep. 2023; 13(1):16235.

PMID: 37758826 PMC: 10533510. DOI: 10.1038/s41598-023-43270-z.